drugset / Trial / NCT05053854
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
NaSingle-groupOpen-labelTreatment
Summary
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
Timeline
- Start
- 2021-12-08
- Primary completion
- 2029-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | 0.1 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.25 mg | Oral |
| Subject | Talazoparib | Small molecule | 0.5 mg | Oral |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |